You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameAmisulpride
Accession NumberDB06288
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionAmisulpride (trade name Solian) is an antipsychotic drug sold by Sanofi-Aventis. It is not approved for use in the United States, but is approved for use in Europe and Australia for the treatment of psychoses and schizophrenia. Additionally, it is approved in Italy for the treatment of dysthymia (under the brand name Deniban). Amisulpride is a selective dopamine antagonist.
Structure
Thumb
Synonyms
4-Amino-N-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-2-methoxybenzamide
4-Amino-N-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-O-anisamide
Aminosultopride
Amisulprida
Amisulpridum
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
DenibanSanofi-Aventis
SolianSanofi-Aventis
Brand mixturesNot Available
SaltsNot Available
Categories
UNII8110R61I4U
CAS number71675-85-9
WeightAverage: 369.479
Monoisotopic: 369.172227057
Chemical FormulaC17H27N3O4S
InChI KeyNTJOBXMMWNYJFB-UHFFFAOYSA-N
InChI
InChI=1S/C17H27N3O4S/c1-4-20-8-6-7-12(20)11-19-17(21)13-9-16(25(22,23)5-2)14(18)10-15(13)24-3/h9-10,12H,4-8,11,18H2,1-3H3,(H,19,21)
IUPAC Name
4-amino-5-(ethanesulfonyl)-N-[(1-ethylpyrrolidin-2-yl)methyl]-2-methoxybenzamide
SMILES
CCN1CCCC1CNC(=O)C1=CC(=C(N)C=C1OC)S(=O)(=O)CC
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as aminobenzoic acids and derivatives. These are benzoic acids (or derivative thereof) containing an amine group attached to the benzene moiety.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassBenzoic acids and derivatives
Direct ParentAminobenzoic acids and derivatives
Alternative Parents
Substituents
  • Salicylamide
  • Aminobenzoic acid or derivatives
  • Methoxyaniline
  • Benzamide
  • Aminobenzamide
  • Methoxybenzene
  • Substituted aniline
  • Phenol ether
  • Benzoyl
  • Anisole
  • Aniline
  • Alkyl aryl ether
  • N-alkylpyrrolidine
  • Primary aromatic amine
  • Sulfonyl
  • Sulfone
  • Pyrrolidine
  • Tertiary aliphatic amine
  • Tertiary amine
  • Secondary carboxylic acid amide
  • Carboxamide group
  • Azacycle
  • Organoheterocyclic compound
  • Ether
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Primary amine
  • Organosulfur compound
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationInvestigated for use/treatment in schizophrenia and schizoaffective disorders, mania in bipolar disorder, and depression.
PharmacodynamicsNot Available
Mechanism of actionAmisulpride binds selectively to dopamine D(2) and D(3) receptors in the limbic system. Low doses of amisulpride preferentially block presynaptic D(2)/D(3)-dopamine autoreceptors, thereby enhancing dopaminergic transmission, whereas higher doses block postsynaptic receptors, thus inhibiting dopaminergic hyperactivity. It may also have 5-ht7 antagonistic effect, useful in depression treatment.
Related Articles
AbsorptionBioavailability is 48% following oral administration.
Volume of distributionNot Available
Protein bindingLow (17%)
MetabolismNot Available
Route of eliminationNot Available
Half lifeApproximately 12 hours
ClearanceNot Available
ToxicityOverdoses of amisulpride have been linked with torsades de pointes.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.864
Blood Brain Barrier+0.9441
Caco-2 permeable-0.7127
P-glycoprotein substrateSubstrate0.7242
P-glycoprotein inhibitor INon-inhibitor0.8209
P-glycoprotein inhibitor IINon-inhibitor0.8668
Renal organic cation transporterNon-inhibitor0.7899
CYP450 2C9 substrateNon-substrate0.794
CYP450 2D6 substrateNon-substrate0.8272
CYP450 3A4 substrateSubstrate0.5667
CYP450 1A2 substrateNon-inhibitor0.8888
CYP450 2C9 inhibitorNon-inhibitor0.8348
CYP450 2D6 inhibitorNon-inhibitor0.8572
CYP450 2C19 inhibitorNon-inhibitor0.8578
CYP450 3A4 inhibitorNon-inhibitor0.8942
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9081
Ames testNon AMES toxic0.5931
CarcinogenicityNon-carcinogens0.6637
BiodegradationNot ready biodegradable0.8868
Rat acute toxicity2.4706 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9398
hERG inhibition (predictor II)Inhibitor0.7128
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point181-182 °CPhysProp
logP1.06MANNHOLD,R ET AL. (1990)
pKa9.37Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.293 mg/mLALOGPS
logP1.5ALOGPS
logP0.25ChemAxon
logS-3.1ALOGPS
pKa (Strongest Acidic)14.03ChemAxon
pKa (Strongest Basic)7.05ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area101.73 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity99.84 m3·mol-1ChemAxon
Polarizability39.82 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis ReferenceUS4401822
General References
  1. Rosenzweig P, Canal M, Patat A, Bergougnan L, Zieleniuk I, Bianchetti G: A review of the pharmacokinetics, tolerability and pharmacodynamics of amisulpride in healthy volunteers. Hum Psychopharmacol. 2002 Jan;17(1):1-13. [PubMed:12404702 ]
  2. Moller HJ: Amisulpride: limbic specificity and the mechanism of antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatry. 2003 Oct;27(7):1101-11. [PubMed:14642970 ]
  3. Weizman T, Pick CG, Backer MM, Rigai T, Bloch M, Schreiber S: The antinociceptive effect of amisulpride in mice is mediated through opioid mechanisms. Eur J Pharmacol. 2003 Oct 8;478(2-3):155-9. [PubMed:14575800 ]
  4. Leucht S, Pitschel-Walz G, Engel RR, Kissling W: Amisulpride, an unusual "atypical" antipsychotic: a meta-analysis of randomized controlled trials. Am J Psychiatry. 2002 Feb;159(2):180-90. [PubMed:11823257 ]
  5. Rehni AK, Singh TG, Chand P: Amisulpride-induced seizurogenic effect: a potential role of opioid receptor-linked transduction systems. Basic Clin Pharmacol Toxicol. 2011 May;108(5):310-7. doi: 10.1111/j.1742-7843.2010.00655.x. Epub 2010 Dec 22. [PubMed:21176108 ]
External Links
ATC CodesN05AL05
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
3,4-MethylenedioxyamphetamineAmisulpride may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.
3,4-MethylenedioxymethamphetamineAmisulpride may decrease the stimulatory activities of 3,4-Methylenedioxymethamphetamine.
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Amisulpride.
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Amisulpride.
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Amisulpride.
AcetophenazineThe risk or severity of adverse effects can be increased when Acetophenazine is combined with Amisulpride.
adipiplonThe risk or severity of adverse effects can be increased when Amisulpride is combined with adipiplon.
AgomelatineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Agomelatine.
AlfaxaloneThe risk or severity of adverse effects can be increased when Amisulpride is combined with Alfaxalone.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Amisulpride.
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Amisulpride.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Amisulpride.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Amisulpride.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Amisulpride.
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Amisulpride.
AmoxapineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Amisulpride.
AmphetamineAmisulpride may decrease the stimulatory activities of Amphetamine.
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Amisulpride.
ArticaineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Articaine.
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Amisulpride.
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Amisulpride.
AzelastineAmisulpride may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Amisulpride.
BaclofenThe risk or severity of adverse effects can be increased when Amisulpride is combined with Baclofen.
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Amisulpride.
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Amisulpride.
BenzphetamineAmisulpride may decrease the stimulatory activities of Benzphetamine.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Amisulpride is combined with Benzyl alcohol.
BifeprunoxThe risk or severity of adverse effects can be increased when Bifeprunox is combined with Amisulpride.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Brexpiprazole is combined with Amisulpride.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Amisulpride.
BrimonidineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Amisulpride.
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Amisulpride.
BrompheniramineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Amisulpride is combined with Brotizolam.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Amisulpride.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Amisulpride.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Amisulpride.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Amisulpride.
ButacaineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Butacaine.
ButalbitalThe risk or severity of adverse effects can be increased when Amisulpride is combined with Butalbital.
ButambenThe risk or severity of adverse effects can be increased when Amisulpride is combined with Butamben.
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Amisulpride.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Amisulpride.
CabergolineThe therapeutic efficacy of Amisulpride can be decreased when used in combination with Cabergoline.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Amisulpride.
CarbinoxamineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Amisulpride.
CariprazineThe risk or severity of adverse effects can be increased when Cariprazine is combined with Amisulpride.
CarisoprodolThe risk or severity of adverse effects can be increased when Amisulpride is combined with Carisoprodol.
CetirizineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Cetirizine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Amisulpride.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Amisulpride.
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Amisulpride.
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Amisulpride.
ChlorphenamineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Chlorphenamine.
ChlorphentermineAmisulpride may decrease the stimulatory activities of Chlorphentermine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Amisulpride.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Amisulpride.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Amisulpride is combined with Chlorzoxazone.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Amisulpride.
CitalopramThe risk or severity of adverse effects can be increased when Amisulpride is combined with Citalopram.
ClemastineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Clemastine.
ClidiniumThe risk or severity of adverse effects can be increased when Amisulpride is combined with Clidinium.
ClobazamThe risk or severity of adverse effects can be increased when Amisulpride is combined with Clobazam.
clomethiazoleThe risk or severity of adverse effects can be increased when Amisulpride is combined with clomethiazole.
ClomipramineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Amisulpride is combined with Clonazepam.
ClonidineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Clonidine.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Amisulpride.
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Amisulpride.
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Amisulpride.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Amisulpride.
CyamemazineThe risk or severity of adverse effects can be increased when Cyamemazine is combined with Amisulpride.
CyclizineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Amisulpride.
CyproheptadineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Cyproheptadine.
DantroleneThe risk or severity of adverse effects can be increased when Amisulpride is combined with Dantrolene.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Amisulpride.
DapoxetineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Dapoxetine.
deramciclaneThe risk or severity of adverse effects can be increased when Amisulpride is combined with deramciclane.
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Amisulpride.
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Amisulpride.
DesloratadineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Desloratadine.
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Amisulpride.
DetomidineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Detomidine.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Dexbrompheniramine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Amisulpride.
DextroamphetamineAmisulpride may decrease the stimulatory activities of Dextroamphetamine.
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Amisulpride.
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Amisulpride.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Amisulpride.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Amisulpride.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Amisulpride.
DifenoxinThe risk or severity of adverse effects can be increased when Amisulpride is combined with Difenoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Amisulpride.
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Amisulpride.
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Amisulpride.
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Amisulpride.
DimenhydrinateThe risk or severity of adverse effects can be increased when Amisulpride is combined with Dimenhydrinate.
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Amisulpride.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Amisulpride.
DoramectinThe risk or severity of adverse effects can be increased when Amisulpride is combined with Doramectin.
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Amisulpride.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Amisulpride.
DoxylamineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when Amisulpride is combined with DPDPE.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Amisulpride.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Amisulpride.
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Amisulpride.
DuloxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Amisulpride.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Amisulpride.
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Amisulpride.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Amisulpride.
EfavirenzThe risk or severity of adverse effects can be increased when Amisulpride is combined with Efavirenz.
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Amisulpride.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Amisulpride.
EntacaponeThe risk or severity of adverse effects can be increased when Amisulpride is combined with Entacapone.
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Amisulpride.
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Amisulpride.
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Amisulpride.
EscitalopramThe risk or severity of adverse effects can be increased when Amisulpride is combined with Escitalopram.
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Amisulpride.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Amisulpride.
EthanolAmisulpride may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Amisulpride.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Amisulpride.
EthosuximideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Amisulpride is combined with Ethotoin.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Amisulpride.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Amisulpride.
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Amisulpride.
EtidocaineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Etidocaine.
EtifoxineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Etifoxine.
EtizolamThe risk or severity of adverse effects can be increased when Amisulpride is combined with Etizolam.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Amisulpride.
EtoperidoneThe risk or severity of adverse effects can be increased when Amisulpride is combined with Etoperidone.
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Amisulpride.
EzogabineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Amisulpride is combined with Felbamate.
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Amisulpride.
FenfluramineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Fenfluramine.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Amisulpride.
FexofenadineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Fexofenadine.
FlibanserinThe risk or severity of adverse effects can be increased when Amisulpride is combined with Flibanserin.
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Amisulpride.
FlunarizineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Amisulpride.
FluoxetineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Amisulpride.
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Amisulpride.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Amisulpride.
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Amisulpride.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Amisulpride is combined with Fluticasone Propionate.
FluvoxamineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Fluvoxamine.
FosphenytoinThe risk or severity of adverse effects can be increased when Amisulpride is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Amisulpride is combined with Fospropofol.
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Amisulpride.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Amisulpride.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Amisulpride is combined with gabapentin enacarbil.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Amisulpride.
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Amisulpride.
GuanfacineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Amisulpride.
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Amisulpride.
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Amisulpride.
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Amisulpride.
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Amisulpride.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Amisulpride.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Amisulpride.
Hydroxyamphetamine hydrobromideAmisulpride may decrease the stimulatory activities of Hydroxyamphetamine hydrobromide.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Amisulpride.
HydroxyzineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Hydroxyzine.
IloperidoneThe risk or severity of adverse effects can be increased when Iloperidone is combined with Amisulpride.
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Amisulpride.
IndalpineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Indalpine.
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Amisulpride.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Amisulpride.
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Amisulpride.
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Amisulpride.
KetobemidoneThe risk or severity of adverse effects can be increased when Amisulpride is combined with Ketobemidone.
LamotrigineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Lamotrigine.
LevetiracetamThe risk or severity of adverse effects can be increased when Amisulpride is combined with Levetiracetam.
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Amisulpride.
LevocabastineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Amisulpride is combined with Levodopa.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Amisulpride.
LevomilnacipranThe risk or severity of adverse effects can be increased when Amisulpride is combined with Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Amisulpride.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Amisulpride.
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Amisulpride.
LisdexamfetamineAmisulpride may decrease the stimulatory activities of Lisdexamfetamine.
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Amisulpride.
LofentanilThe risk or severity of adverse effects can be increased when Amisulpride is combined with Lofentanil.
LoratadineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Amisulpride.
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Amisulpride.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Amisulpride.
Lu AA21004The risk or severity of adverse effects can be increased when Amisulpride is combined with Lu AA21004.
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Amisulpride.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Amisulpride.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Amisulpride is combined with Magnesium Sulfate.
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Amisulpride.
MeclizineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Medetomidine.
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Amisulpride.
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Amisulpride.
MephentermineAmisulpride may decrease the stimulatory activities of Mephentermine.
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Amisulpride.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Amisulpride.
MequitazineAmisulpride may increase the arrhythmogenic activities of Mequitazine.
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Amisulpride.
MetaxaloneThe risk or severity of adverse effects can be increased when Amisulpride is combined with Metaxalone.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Amisulpride.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Amisulpride.
MethamphetamineAmisulpride may decrease the stimulatory activities of Methamphetamine.
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Amisulpride.
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Amisulpride.
MethocarbamolThe risk or severity of adverse effects can be increased when Amisulpride is combined with Methocarbamol.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Amisulpride.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Amisulpride.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Amisulpride.
MethsuximideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Methsuximide.
MethylphenidateThe risk or severity of adverse effects can be increased when Amisulpride is combined with Methylphenidate.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Amisulpride.
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Amisulpride.
MetyrosineAmisulpride may increase the sedative activities of Metyrosine.
MetyrosineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Amisulpride.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Amisulpride.
MilnacipranThe risk or severity of adverse effects can be increased when Amisulpride is combined with Milnacipran.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Amisulpride.
MirtazapineAmisulpride may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Amisulpride.
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Amisulpride.
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Amisulpride.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Amisulpride.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Amisulpride.
NabiloneThe risk or severity of adverse effects can be increased when Amisulpride is combined with Nabilone.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Amisulpride.
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Amisulpride.
NefazodoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Amisulpride.
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Amisulpride.
Nitrous oxideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Nitrous oxide.
NormethadoneThe risk or severity of adverse effects can be increased when Amisulpride is combined with Normethadone.
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Amisulpride.
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Amisulpride.
OlopatadineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Olopatadine.
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Amisulpride.
OpiumThe risk or severity of adverse effects can be increased when Amisulpride is combined with Opium.
OrphenadrineAmisulpride may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Amisulpride.
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Amisulpride.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Amisulpride.
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Amisulpride.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Amisulpride.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Amisulpride.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Amisulpride.
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Amisulpride.
ParaldehydeAmisulpride may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Amisulpride.
ParoxetineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Paroxetine.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Amisulpride.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Amisulpride.
PerampanelThe risk or severity of adverse effects can be increased when Amisulpride is combined with Perampanel.
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Amisulpride.
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Amisulpride.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Amisulpride.
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Amisulpride.
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Amisulpride.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Amisulpride is combined with Phenoxyethanol.
PhentermineAmisulpride may decrease the stimulatory activities of Phentermine.
PhenytoinThe risk or severity of adverse effects can be increased when Amisulpride is combined with Phenytoin.
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Amisulpride.
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Amisulpride.
PipotiazineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Amisulpride.
PizotifenThe risk or severity of adverse effects can be increased when Amisulpride is combined with Pizotifen.
PomalidomideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Pomalidomide.
PramipexoleAmisulpride may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Pramocaine.
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Amisulpride.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Amisulpride.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Amisulpride.
PrimidoneThe risk or severity of adverse effects can be increased when Amisulpride is combined with Primidone.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Amisulpride.
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Amisulpride.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Amisulpride.
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Amisulpride.
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Amisulpride.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Amisulpride.
PropericiazineThe risk or severity of adverse effects can be increased when Propericiazine is combined with Amisulpride.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Amisulpride.
PropoxycaineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Propoxycaine.
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Amisulpride.
PSD502The risk or severity of adverse effects can be increased when Amisulpride is combined with PSD502.
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Amisulpride.
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Amisulpride.
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Amisulpride.
RamelteonThe risk or severity of adverse effects can be increased when Amisulpride is combined with Ramelteon.
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Amisulpride.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Amisulpride.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Amisulpride.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Amisulpride.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Amisulpride.
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Amisulpride.
RomifidineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Romifidine.
RopiniroleAmisulpride may increase the sedative activities of Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Amisulpride.
RotigotineAmisulpride may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Amisulpride.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Amisulpride.
ScopolamineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Scopolamine.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Amisulpride.
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Amisulpride.
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Amisulpride.
SertralineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Amisulpride.
Sodium oxybateThe risk or severity of adverse effects can be increased when Amisulpride is combined with Sodium oxybate.
StiripentolThe risk or severity of adverse effects can be increased when Amisulpride is combined with Stiripentol.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Amisulpride.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Amisulpride.
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Amisulpride.
SuvorexantThe risk or severity of adverse effects can be increased when Amisulpride is combined with Suvorexant.
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Amisulpride.
TasimelteonThe risk or severity of adverse effects can be increased when Amisulpride is combined with Tasimelteon.
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Amisulpride.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Amisulpride.
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Amisulpride.
TetracaineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Tetracaine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Amisulpride.
ThalidomideAmisulpride may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Amisulpride.
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Amisulpride.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Amisulpride.
ThioproperazineThe risk or severity of adverse effects can be increased when Thioproperazine is combined with Amisulpride.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Amisulpride.
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Amisulpride.
TiagabineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Tiagabine.
TiletamineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Tiletamine.
TizanidineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Tizanidine.
TolcaponeThe risk or severity of adverse effects can be increased when Amisulpride is combined with Tolcapone.
TopiramateThe risk or severity of adverse effects can be increased when Amisulpride is combined with Topiramate.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Amisulpride.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Amisulpride.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Amisulpride.
TrazodoneThe risk or severity of adverse effects can be increased when Amisulpride is combined with Trazodone.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Amisulpride.
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Amisulpride.
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Amisulpride.
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Amisulpride.
TriprolidineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Triprolidine.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Amisulpride.
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Amisulpride.
VigabatrinThe risk or severity of adverse effects can be increased when Amisulpride is combined with Vigabatrin.
VilazodoneThe risk or severity of adverse effects can be increased when Amisulpride is combined with Vilazodone.
VortioxetineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Vortioxetine.
XylazineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Xylazine.
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Amisulpride.
ZiconotideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Ziconotide.
ZimelidineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Zimelidine.
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Amisulpride.
ZolazepamThe risk or severity of adverse effects can be increased when Amisulpride is combined with Zolazepam.
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Amisulpride.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Amisulpride.
ZonisamideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Amisulpride.
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Amisulpride.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Amisulpride.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Potassium channel regulator activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name:
DRD2
Uniprot ID:
P14416
Molecular Weight:
50618.91 Da
References
  1. Rosenzweig P, Canal M, Patat A, Bergougnan L, Zieleniuk I, Bianchetti G: A review of the pharmacokinetics, tolerability and pharmacodynamics of amisulpride in healthy volunteers. Hum Psychopharmacol. 2002 Jan;17(1):1-13. [PubMed:12404702 ]
  2. Horacek J, Bubenikova-Valesova V, Kopecek M, Palenicek T, Dockery C, Mohr P, Hoschl C: Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs. 2006;20(5):389-409. [PubMed:16696579 ]
  3. Seeman P: Atypical antipsychotics: mechanism of action. Can J Psychiatry. 2002 Feb;47(1):27-38. [PubMed:11873706 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase. Promotes cell proliferation.
Gene Name:
DRD3
Uniprot ID:
P35462
Molecular Weight:
44224.335 Da
References
  1. Rosenzweig P, Canal M, Patat A, Bergougnan L, Zieleniuk I, Bianchetti G: A review of the pharmacokinetics, tolerability and pharmacodynamics of amisulpride in healthy volunteers. Hum Psychopharmacol. 2002 Jan;17(1):1-13. [PubMed:12404702 ]
  2. Horacek J, Bubenikova-Valesova V, Kopecek M, Palenicek T, Dockery C, Mohr P, Hoschl C: Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs. 2006;20(5):389-409. [PubMed:16696579 ]
  3. Seeman P: Atypical antipsychotics: mechanism of action. Can J Psychiatry. 2002 Feb;47(1):27-38. [PubMed:11873706 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor is mediated by G proteins that stimulate adenylate cyclase.
Gene Name:
HTR7
Uniprot ID:
P34969
Molecular Weight:
53554.43 Da
References
  1. Abbas AI, Hedlund PB, Huang XP, Tran TB, Meltzer HY, Roth BL: Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo. Psychopharmacology (Berl). 2009 Jul;205(1):119-28. doi: 10.1007/s00213-009-1521-8. Epub 2009 Apr 1. [PubMed:19337725 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Virus receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates...
Gene Name:
HTR2A
Uniprot ID:
P28223
Molecular Weight:
52602.58 Da
References
  1. Tyson PJ, Roberts KH, Mortimer AM: Are the cognitive effects of atypical antipsychotics influenced by their affinity to 5HT-2A receptors? Int J Neurosci. 2004 Jun;114(6):593-611. [PubMed:15204055 ]
Comments
comments powered by Disqus
Drug created on March 19, 2008 10:22 / Updated on August 17, 2016 12:24